Non-infusional 5-fluorouracil, doxorubicin and cisplatin in the treatment of locally advanced or metastatic gastro-oesophageal adenocarcinoma

Απλή σελίδα τεκμηρίου
dc.contributor.authorPentheroudakis, G.en
dc.contributor.authorLim, K. C.en
dc.contributor.authorDunlop, D. J.en
dc.contributor.authorSoukop, M.en
dc.contributor.authorEatock, M. M.en
dc.date.accessioned2015-11-24T19:01:50Z
dc.date.available2015-11-24T19:01:50Z
dc.identifier.issn0284-186X-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/19731
dc.rightsDefault Licence-
dc.subjectAdenocarcinoma/*drug therapy/pathologyen
dc.subjectAdulten
dc.subjectAntineoplastic Combined Chemotherapy Protocols/administration &en
dc.subjectdosage/*therapeutic useen
dc.subjectCisplatin/administration & dosageen
dc.subjectDisease Progressionen
dc.subjectDisease-Free Survivalen
dc.subjectDoxorubicin/administration & dosageen
dc.subjectEsophageal Neoplasms/*drug therapy/pathologyen
dc.subjectFemaleen
dc.subjectFluorouracil/administration & dosageen
dc.subjectHumansen
dc.subjectInjections, Intravenousen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectNeutropenia/chemically induceden
dc.subjectRetrospective Studiesen
dc.subjectStomach Neoplasms/*drug therapy/pathologyen
dc.subjectTreatment Outcomeen
dc.titleNon-infusional 5-fluorouracil, doxorubicin and cisplatin in the treatment of locally advanced or metastatic gastro-oesophageal adenocarcinomaen
heal.abstractTo reduce the Hickman line-associated morbidity of continuous infusion 5-fluorouracil combined with epirubicin and cisplatin (ECF) and to investigate the need for infusional regimens, we conducted a retrospective study in patients with advanced gastro-oesophageal adenocarcinoma. Thirty-six patients, with histologically proven irresectable gastro-oesophageal adenocarcinoma were given: 60 mg/m2 cisplatin on day 1, 35 mg/m2 doxorubicin on day 1 and 500 mg/m2 5-fluorouracil on days 1 and 8 (NIACF) every 3-weeks. A median of 3 cycles was administered. The principal toxicity was myelosuppression with grade III/IV neutropenia in 47% of cycles. Neutropenic fever occurred in 5% of the cycles: non-haematological toxicity was mild and there were no treatment-related deaths. Administered dose intensity was 96.1% for doxorubicin, 93.6% for cisplatin and 90.5% for 5-fluorouracil. There were 16 partial responses and 1 complete response (overall response rate 47%, 95% confidence interval CI 31-63%); 8 patients had stable disease. Median progression-free and overall survival rates were 5 months (95% CI 4-6) and 8 months (95% CI 6-10), respectively. NIACF is a well-tolerated regimen in advanced gastro-oesophageal adenocarcinoma that precludes the need for central venous access, with activity similar to that observed with ECF.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/11859986-
heal.identifier.secondaryhttp://informahealthcare.com/doi/pdfplus/10.1080/02841860152703490-
heal.journalNameActa Oncolen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2001-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ